Avalyn Pharma (NASDAQ:AVLN) Trading Down 8.1% – Should You Sell?

Avalyn Pharma Inc. (NASDAQ:AVLN)’s stock price fell 8.1% during mid-day trading on Monday . The company traded as low as $26.01 and last traded at $26.45. 51,037 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 346,334 shares. The stock had previously closed at $28.78.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AVLN. Morgan Stanley began coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 price target on the stock. Zacks Research raised Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Guggenheim began coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Jefferies Financial Group began coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 price target on the stock. Finally, Evercore began coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Avalyn Pharma currently has an average rating of “Buy” and an average target price of $59.00.

Avalyn Pharma Stock Performance

Insider Activity

In other news, Director Jill Carroll acquired 277,778 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were acquired at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the purchase, the director directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 14.55% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.